dc.contributor.author | Ianevski, Aleksandr | |
dc.contributor.author | Ahmad, Shahzaib | |
dc.contributor.author | Anunnitipat, Kraipit | |
dc.contributor.author | Oksenych, Valentyn | |
dc.contributor.author | Zusinaite, Eva | |
dc.contributor.author | Tenson, Tanel | |
dc.contributor.author | Bjørås, Magnar | |
dc.contributor.author | Kainov, Denis | |
dc.date.accessioned | 2024-07-16T09:28:45Z | |
dc.date.available | 2024-07-16T09:28:45Z | |
dc.date.created | 2022-12-15T14:55:39Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Cellular and Molecular Life Sciences (CMLS). 2022, 79 (12), . | en_US |
dc.identifier.issn | 1420-682X | |
dc.identifier.uri | https://hdl.handle.net/11250/3141455 | |
dc.description.abstract | The viral epidemics and pandemics have stimulated the development of known and the discovery of novel antiviral agents. About a hundred mono- and combination antiviral drugs have been already approved, whereas thousands are in development. Here, we briefly reviewed 7 classes of antiviral agents: neutralizing antibodies, neutralizing recombinant soluble human receptors, antiviral CRISPR/Cas systems, interferons, antiviral peptides, antiviral nucleic acid polymers, and antiviral small molecules. Interferons and some small molecules alone or in combinations possess broad-spectrum antiviral activity, which could be beneficial for treatment of emerging and re-emerging viral infections. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.relation.uri | https://link.springer.com/article/10.1007/s00018-022-04635-1 | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Seven classes of antiviral agents | en_US |
dc.title.alternative | Seven classes of antiviral agents | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 9 | en_US |
dc.source.volume | 79 | en_US |
dc.source.journal | Cellular and Molecular Life Sciences (CMLS) | en_US |
dc.source.issue | 12 | en_US |
dc.identifier.doi | 10.1007/s00018-022-04635-1 | |
dc.identifier.cristin | 2093893 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |